<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Geriatric bipolar disorder: Maintenance treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Geriatric bipolar disorder: Maintenance treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Geriatric bipolar disorder: Maintenance treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martha Sajatovic, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peijun Chen, MD, MPH, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1033803"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical features and treatment of older bipolar patients differ from those of younger patients [<a href="#rid1">1</a>]. Geriatric patients constitute up to 25 percent of all bipolar patients [<a href="#rid2">2</a>], and the absolute number of geriatric bipolar patients is expected to increase as the world’s population ages over the next several decades [<a href="#rid3">3,4</a>].</p><p>This topic reviews the maintenance treatment of geriatric bipolar disorder. The epidemiology, pathogenesis, clinical features, assessment, diagnosis, and acute treatment of geriatric bipolar disorder are discussed separately, as are the clinical features, diagnosis, acute treatment, and maintenance treatment of bipolar disorder in mixed-age patients.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14650.html" rel="external">"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/678.html" rel="external">"Bipolar disorder in adults: Epidemiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p></p><p class="headingAnchor" id="H1033810"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H1292379"><span class="h2">Geriatric bipolar disorder</span><span class="headingEndMark"> — </span>The minimum age used to define geriatric bipolar disorder is generally 60 years [<a href="#rid5">5</a>]. However, some authorities use an age cut-off of 50, 55, or 65 years [<a href="#rid6">6</a>]. Geriatric bipolar disorder includes both aging patients whose mood disorder presented earlier in life, and patients whose mood disorder presents for the first time in later life [<a href="#rid1">1,7</a>]. A summary statement from the International Society for Bipolar Disorders taskforce focused upon geriatric bipolar disorder used the term “older age bipolar disorder” to describe this group of patients [<a href="#rid8">8</a>].</p><p>Bipolar disorder is characterized by episodes of major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 1</a>), mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 2</a>), and hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 3</a>) [<a href="#rid9">9</a>]. However, the clinical features of bipolar disorder are different for older and younger patients in that [<a href="#rid1">1,10-13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive impairment is more common and severe in geriatric patients</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid general medical illnesses are more common in older patients</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive sexual interest and behavior during manic or hypomanic episodes appear to be less common in older patients</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid anxiety and substance use disorders may be less common in geriatric patients</p><p></p><p>The clinical features and diagnosis of geriatric bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/14650.html" rel="external">"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1292399"><span class="h2">Remission</span><span class="headingEndMark"> — </span>Remission is defined as the resolution of mood symptoms, or improvement to the point that only one or two symptoms of mild intensity persist. If psychotic features (delusions or hallucinations) are also present, resolution of the psychosis is required for remission. The rate of remission from geriatric bipolar mood episodes is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Recovery from mood episodes (prognosis)'</a>.)</p><p class="headingAnchor" id="H93062938"><span class="h1">INDICATION</span><span class="headingEndMark"> — </span>Maintenance treatment is indicated for nearly all patients with geriatric bipolar disorder, based upon observational studies that have found patients who remit from a mood episode are at high risk for suffering another episode:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple studies of geriatric bipolar patients suggest that within a 12-month period, approximately 20 percent will sustain four or more recurrences [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study of 220 bipolar patients assessed course of illness for approximately 40 years and found that the median number of lifetime episodes was 10 and that the risk of recurrence remained constant up to the age of 70 years or more [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 26 geriatric bipolar patients found that 38 percent had a lifetime history of at least three mood episodes [<a href="#rid17">17</a>].</p><p></p><p>Maintenance treatment for geriatric bipolar patients is consistent with practice guidelines from the National Institute for Health and Clinical Excellence [<a href="#rid18">18</a>], Canadian Network for Mood and Anxiety Treatments [<a href="#rid19">19</a>], International Society for Bipolar Disorders [<a href="#rid20">20</a>], British Association for Psychopharmacology [<a href="#rid21">21</a>], and Royal Australian and New Zealand College of Psychiatrists [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1033817"><span class="h1">CHOOSING TREATMENT</span></p><p class="headingAnchor" id="H173801633"><span class="h2">Choosing pharmacotherapy following recovery from mood episodes</span><span class="headingEndMark"> — </span>Following recovery from geriatric bipolar mood episodes, maintenance treatment usually includes pharmacotherapy [<a href="#rid19">19,22</a>]. Acutely ill patients who remit with a medication regimen should generally be maintained on the same drugs and doses. However, for patients who recover from an episode of major depression with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> plus <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> (the antidepressant/second generation antipsychotic combination that we generally use for refractory patients), fluoxetine is generally tapered and discontinued within a few months of remission. (See <a class="local">'Following recovery from bipolar major depression'</a> below.)</p><p>For patients who recover from geriatric bipolar mood episodes, but do not tolerate maintenance treatment with the drug regimen that achieved recovery, we suggest switching to maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> monotherapy. This approach is consistent with practice guidelines from the International Society for Bipolar Disorders for older-age bipolar disorder [<a href="#rid20">20</a>]. Target serum concentrations depend upon the patient’s age:</p><p class="bulletIndent1"><span class="glyph">●</span>60 to 79 years – 0.4 to 0.8 mEq/L (0.4 to 0.8 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>80 years and over – 0.4 to 0.7 mEq/L (0.4 to 0.7 mmol/L)</p><p></p><p>The guidelines also state that reasonable alternatives to <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> include monotherapy with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid20">20</a>]. In addition, if patients receiving lithium monotherapy require add-on pharmacotherapy, the preferred choices include lamotrigine, quetiapine, or valproate.</p><p>Comorbid diseases, concomitant medications, and age-related physiologic changes often alter a drug’s pharmacodynamics and pharmacokinetics, which can affect therapeutic and adverse responses. Pharmacologic issues in older bipolar patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/111402.html" rel="external">"Geriatric bipolar disorder: General principles of treatment", section on 'Pharmacologic issues'</a>.)</p><p class="headingAnchor" id="H5969178"><span class="h3">Evidence of efficacy</span><span class="headingEndMark"> — </span>In the adult population (eg, age 18 to 65 years), multiple randomized trials have demonstrated the efficacy of different medications for preventing recurrent episodes of mania/hypomania and major depression. These studies are discussed separately in the context of choosing medications for maintenance treatment of adults with bipolar disorder. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p>Studies of maintenance treatment for geriatric bipolar disorder are limited. Evidence for the efficacy of maintenance pharmacotherapy for geriatric bipolar disorder includes subgroup analyses of older patients in randomized trials conducted with mixed-age patients (18 to 65 years):</p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of two 18-month randomized trials compared <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, and placebo in mixed-age bipolar patients who were stable for at least four weeks [<a href="#rid23">23</a>]. In the subgroup of 98 older patients, time to intervention for an emerging episode of mania, hypomania, or mixed (concurrent manic and depressive symptoms) mania was longer with lithium (modal dose 750 mg per day) than placebo [<a href="#rid24">24</a>]. Time to intervention for an emerging episode of major depression was significantly longer with lamotrigine (modal dose 240 mg per day) than placebo. These results were consistent with those from the mixed-age patients. Among older patients, withdrawal from treatment due to side effects occurred most often with lithium, followed by lamotrigine and placebo (29 versus 18 and 13 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An open-label, two-year randomized maintenance trial (Bipolar Affective disorder: <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a>/Anticonvulsant Evaluation; BALANCE) compared lithium monotherapy, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> monotherapy, and lithium plus valproate in 330 bipolar mixed-age patients [<a href="#rid25">25</a>]. Lithium monotherapy and combination treatment were superior to valproate alone, and subgroup analyses found the results did not differ significantly between older and younger patients.</p><p></p><p>Observational studies also suggest that maintenance treatment may be effective. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed-age patients with acute bipolar major depression, who completed six weeks of treatment with <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> monotherapy or lurasidone plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> as part of a randomized trial, were prospectively followed for up to six months [<a href="#rid26">26</a>]. During the six-month open-label follow-up, patients received lurasidone (20 to 120 mg/day) once daily in the evening, either as monotherapy or combined with lithium or valproate. In the subgroup of older patients (n = 141), efficacy of lurasidone was maintained [<a href="#rid27">27</a>]. In addition, pharmacotherapy was generally well tolerated, such that discontinuation of treatment due to adverse effects occurred in 8 percent. These results were consistent with those from the mixed-age patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 281 patients aged 55 years or more, with bipolar disorder or unipolar major depression, 44 (16 percent) took <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for a mean duration of 13 years, as part of their pharmacotherapy regimen [<a href="#rid28">28</a>]. Among the 44 patients treated with lithium, the diagnosis was bipolar disorder in 33 (75 percent), and unipolar major depression in 11 (25 percent). After controlling for potential confounding factors (eg, demographics, diagnosis, and other psychotropic drugs), the analyses found that use of lithium was associated with less severe illness, including less intense symptoms of depression. In addition, there was a trend for fewer psychiatric hospitalizations in the past year among patients who received lithium.</p><p></p><p class="headingAnchor" id="H1861552"><span class="h3">Following recovery from bipolar major depression</span><span class="headingEndMark"> — </span>Acutely ill patients who remit with a medication regimen should generally be maintained on the same drugs and doses. However, for geriatric bipolar patients with major depression who remit with the combination of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> (the antidepressant/second generation antipsychotic combination that we generally use for refractory patients), and then remain stable for two to six months, we suggest tapering fluoxetine by 10 mg per week until it is discontinued, and continuing olanzapine. The reason is that maintenance antidepressants may possibly induce mania or hypomania [<a href="#rid29">29,30</a>]. If symptoms of depression recur during the taper, the dose should be titrated back up to the full dose used to initially achieve remission. If a full-blown depressive episode develops despite increasing the dose and does not improve within four to eight weeks, the relapse is treated as a new acute episode; acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p>For geriatric bipolar patients with major depression who remit with the combination of <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> and <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and then develop manic or hypomanic symptoms during maintenance treatment, fluoxetine should be abruptly discontinued and olanzapine continued. If a full-blown manic or hypomanic episode develops despite discontinuing fluoxetine and does not improve within four to eight weeks, the relapse is treated as a new acute episode; acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a>.)</p><p class="headingAnchor" id="H1861594"><span class="h3">Treatment following remission with electroconvulsive therapy</span><span class="headingEndMark"> — </span>For geriatric bipolar patients who remit with electroconvulsive therapy (ECT), we suggest maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, based upon its efficacy in the subgroup of older patients who participated in randomized trials with mixed-age adult bipolar patients (18 to 65 years) [<a href="#rid24">24,25</a>]. However, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is a reasonable alternative. The maintenance drug is started the day after ECT is completed, unless the patient is suffering cognitive impairment secondary to ECT, in which case maintenance pharmacotherapy is delayed until the impairment has dissipated. The dose and side effects of lithium and lamotrigine are discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Treatment resistance'</a>.)</p><p>For geriatric bipolar patients who remit with ECT and cannot tolerate maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, reasonable alternatives include <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, or <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, based upon their efficacy in mixed age patients. There is no evidence of superior efficacy among these alternatives; the choice is thus guided by side effect profiles, potential drug-drug interactions, comorbid general medical conditions, patient preference, and cost. The dose and side effects of these alternatives are discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Second-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Refractory patients'</a>.)</p><p>Maintenance ECT should be offered to geriatric bipolar patients who repeatedly remit with ECT and then relapse during maintenance pharmacotherapy [<a href="#rid31">31</a>]. Maintenance ECT is discussed separately. (See  <a class="medical medical_review" href="/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Continuation and maintenance ECT'</a>.)</p><p class="headingAnchor" id="H5969969"><span class="h3">Managing intolerable side effects</span><span class="headingEndMark"> — </span>Geriatric bipolar patients who cannot tolerate maintenance treatment with the minimum target dose of a medication are generally switched to another medication. For patients not receiving <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we and others suggest switching to lithium [<a href="#rid1">1</a>], based upon its efficacy in analyses of results from older patients who participated in randomized trials with mixed-age adult bipolar patients (18 to 65 years) [<a href="#rid24">24,25</a>]. However, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is a reasonable alternative. The failed medication is generally tapered and discontinued over one to two weeks by the same amount for each dose decrease. As an example, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> 15 mg per day is decreased by 5 mg per day, every one to three days. At the same time, lithium or lamotrigine is started and titrated up. The dose and side effects of lithium and lamotrigine are discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Treatment resistance'</a>.)</p><p>For remitted geriatric bipolar patients who cannot tolerate maintenance treatment with the medication that induced remission and are also intolerant of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, reasonable alternatives include <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, or <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>. There is no evidence of superior efficacy among these alternatives; the choice is thus guided by side effect profiles, potential drug-drug interactions, comorbid general medical conditions, patient preference, and cost. The dose and side effects of these alternatives are discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Second-line medications'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Refractory patients'</a>.)</p><p>For geriatric bipolar patients who remit with a medication combination and cannot tolerate minimum target doses, we suggest tapering and discontinuing the drug that is most troublesome and continuing with the remaining drug. The failed drug is generally tapered and discontinued over one to two weeks by the same amount for each dose decrease. At the same time, the dose of the remaining drug should be increased within the target dose range as tolerated. The dose and side effects of medications are discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p class="headingAnchor" id="H2728176"><span class="h3">Cognitive impairment</span><span class="headingEndMark"> — </span>Cognition is commonly impaired in euthymic, geriatric bipolar patients [<a href="#rid32">32,33</a>]. Although no high quality trials have demonstrated that maintenance treatment can improve or preserve cognition in geriatric bipolar patients, observational studies suggest that long-term treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> may have neuroprotective effects and reduce the risk of developing neurocognitive disorders. As an example, a meta-analysis of five observational studies found that dementia was half as likely to occur in patients treated with lithium (n &gt;6000), compared with patients not treated with lithium (n &gt;43,000; odds ratio 0.5, 95% CI 0.4-0.7) [<a href="#rid33">33</a>]. In the largest of the five studies (n &gt;41,000 patients, age ≥50 years), which controlled for potential confounding factors (eg, age, comorbid general medical disorders, and use of other psychotropic drugs), the incidence of dementia was 23 percent less in patients who received lithium for approximately one year, compared with patients who did not (hazard ratio 0.77, 95% CI 0.60-0.99) [<a href="#rid34">34</a>].</p><p>Other observational studies have found that <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> reduced the risk of neurocognitive disorder in patients with bipolar disorder to the level of the general population [<a href="#rid35">35</a>]. In addition, a 12-month randomized trial compared lithium (serum concentration of 0.25 to 0.50 mEq/L [0.25 to 0.50 mmol/L]) with placebo in patients with mild neurocognitive disorder but without bipolar disorder (n = 45), and found that cognitive function was superior with lithium [<a href="#rid36">36</a>].</p><p>The specific cognitive deficits observed in geriatric bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/14650.html" rel="external">"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Cognitive impairment'</a>.)</p><p class="headingAnchor" id="H87479527"><span class="h2">Adjunctive psychotherapy</span><span class="headingEndMark"> — </span>We suggest that older bipolar patients receiving maintenance pharmacotherapy also receive psychotherapy that focuses upon [<a href="#rid31">31,37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Managing bipolar disorder</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Accepting the illness and the limitations it imposes</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adhering to treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detecting and reporting prodromal symptoms </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limiting or eliminating use of alcohol</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eliminating drugs of abuse (eg, cannabis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regulating sleep</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Managing interpersonal difficulties</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improving self-esteem</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-related issues (eg, changing occupational and social roles, loss of family members and friends, reduced financial resources, or decreased functioning)</p><p></p><p>Although pharmacotherapy is the cornerstone of maintenance treatment for bipolar disorder, adjunctive psychotherapy improves outcomes compared with pharmacotherapy alone in randomized trials with mixed-age adults (18 to 65 years). Thus, several practice guidelines recommend adjunctive psychotherapy. Choosing an adjunctive maintenance psychotherapy (eg, psychoeducation) is discussed further. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Choosing adjunctive psychotherapy'</a>.)</p><p class="headingAnchor" id="H87479534"><span class="h3">Adherence</span><span class="headingEndMark"> — </span>Many geriatric bipolar patients do not adhere to treatment (although their adherence generally exceeds that of younger patients) [<a href="#rid38">38</a>]. A study of 6461 older bipolar patients found that 19 percent partially adhered to treatment and 20 percent were nonadherent, and that comorbid substance abuse was associated with nonadherence. Poor adherence probably increases the risk of recurrence.</p><p>Strategies for improving adherence are discussed separately. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Management'</a>.)</p><p class="headingAnchor" id="H361191963"><span class="h2">Monitoring the patient</span><span class="headingEndMark"> — </span>Remitted geriatric bipolar patients should be evaluated regularly and monitored for recurrence of manic and depressive symptoms as well as medication side effects and cognitive decline. Particular attention is given to suicidal ideation and to psychotic symptoms. Older patients often require more vigilant monitoring than do younger patients [<a href="#rid39">39</a>].</p><p>For geriatric bipolar patients who remit and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one to three more visits, then every month for one to three visits, and then every two months for one to three visits. Continuously stable patients can ultimately be seen every three to six months. More frequent visits should be scheduled for patients who develop symptoms or side effects; monitoring acutely ill patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'General principles'</a>.)</p><p>For patients who receive maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest that monitoring include the following laboratory tests and clinical assessments [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Every three to six months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> level</p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Estimated glomerular filtration rate</p><p class="bulletIndent2"><span class="glyph">•</span>Blood urea nitrogen</p><p class="bulletIndent2"><span class="glyph">•</span>Tremor</p><p class="bulletIndent2"><span class="glyph">•</span>Gait</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annually</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid function</p><p class="bulletIndent2"><span class="glyph">•</span>Fasting glucose</p><p class="bulletIndent2"><span class="glyph">•</span>Fasting cholesterol </p><p class="bulletIndent2"><span class="glyph">•</span>Triglycerides</p><p class="bulletIndent2"><span class="glyph">•</span>Calcium</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count</p><p class="bulletIndent2"><span class="glyph">•</span>Weight and waist circumference</p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive screen (see  <a class="medical medical_review" href="/d/html/14058.html" rel="external">"Mental status scales to evaluate cognition"</a>)</p><p></p><p>This approach is consistent with practice guidelines from the International Society for Bipolar Disorders for older-age bipolar disorder [<a href="#rid20">20</a>].</p><p>Management of patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> who develop renal toxicity (eg, arginine vasopressin resistance [previously called nephrogenic diabetes insipidus] or lithium nephropathy) or thyroid toxicity is discussed separately. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a> and  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid"</a>.)</p><p class="headingAnchor" id="H253436"><span class="h2">Duration and discontinuation</span><span class="headingEndMark"> — </span>Based upon clinical experience, most geriatric bipolar patients require maintenance treatment for many years, and some patients require it for their entire lives. However, the duration is not established and is generally longer in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Residual symptoms, particularly suicidal ideation</p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing comorbid psychopathology </p><p class="bulletIndent1"><span class="glyph">●</span>Psychosocial stressors</p><p class="bulletIndent1"><span class="glyph">●</span>A history of suicide attempts</p><p class="bulletIndent1"><span class="glyph">●</span>A greater number of prior mood episodes</p><p class="bulletIndent1"><span class="glyph">●</span>A history of longer or more severe (eg, psychotic) mood episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Onset of bipolar disorder at an early age (eg, ≤30 years)</p><p></p><p>If the decision is made to discontinue maintenance treatment, we suggest slowly tapering the regimen to increase the probability of detecting incipient mood symptoms before a full-blown episode recurs. For geriatric bipolar patients who remit with monotherapy, we taper the medication over one month. Based upon clinical experience, we decrease the dose each week by approximately 25 percent of the dose used during maintenance treatment. As an example, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> 1200 mg per day is reduced by 300 mg per day each week until it is discontinued. If symptoms recur during the taper, the dose should be titrated back up to the full dose used initially to achieve remission. If full-blown mania develops despite increasing the dose and does not improve within four weeks, or if a full-blown depressive episode develops and does not improve within four to eight weeks, the recurrence is treated as a new acute episode. Acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p>Discontinuing a maintenance medication combination begins by tapering the medication that is more difficult to use because of side effects or drug-drug interactions. We generally taper the medication over one month, decreasing the dose each week by approximately 25 percent of the dose used during maintenance treatment. If mood symptoms recur during the taper, the dose should be titrated back up to the full dose used initially to achieve remission. If a full-blown manic episode develops despite increasing the dose and does not improve within four weeks, or if a full-blown depressive episode develops and does not improve within four to eight weeks, the recurrence is treated as a new acute episode. Acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p>Geriatric bipolar patients who successfully discontinue one medication from their pharmacotherapy combination should be monitored for one to six months prior to discontinuing the remaining medication. If mood symptoms recur, we suggest restarting and titrating up the discontinued drug to the full dose used initially to achieve remission. If a full-blown mania develops despite increasing the dose and does not improve within four weeks, or if a full-blown depressive episode develops and does not improve within four to eight weeks, the recurrence is treated as a new acute episode. Acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p>Geriatric bipolar patients who successfully taper and discontinue one medication from their pharmacotherapy combination and remain stable for one to six months can then be tapered off their remaining medication. We suggest tapering the medication over one month, decreasing the dose each week by approximately 25 percent of the dose used during maintenance treatment. If mood symptoms recur during the taper, the dose should be titrated back up to the full dose used initially to achieve remission. If a full-blown manic episode develops despite increasing the dose and does not improve within four weeks, or if a full-blown depressive episode develops and does not improve within four to eight weeks, the recurrence is treated as a new acute episode. Acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p class="headingAnchor" id="H361192038"><span class="h1">TREATING RECURRENCES</span><span class="headingEndMark"> — </span>Recurrent symptoms or mood episodes during maintenance pharmacotherapy for geriatric bipolar disorder are initially treated by optimizing medication doses [<a href="#rid31">31,40</a>]. This includes ensuring serum concentrations are in the therapeutic range for medications such as <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, as well as increasing the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene. For medications that do not have an established therapeutic serum concentration, such as <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> or second-generation antipsychotics, the dose can be increased within the target dose range.</p><p>If a geriatric bipolar manic episode recurs during maintenance pharmacotherapy and optimizing the dose does not control symptoms within two to four weeks, the recurrence is treated as a new acute episode. If a geriatric bipolar depressive episode recurs during maintenance pharmacotherapy and optimizing the dose does not control symptoms within two to eight weeks, the recurrence is treated as a new acute episode. Acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p>For patients with geriatric bipolar disorder who decide to stop maintenance treatment and successfully taper and discontinue their medication regimen, but subsequently relapse, we suggest restarting the same regimen that was discontinued. The relapse is treated as a new acute episode; acute treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2179988210"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H13496090"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Information for patients (patient education) is discussed separately. (See  <a class="medical medical_review" href="/d/html/111402.html" rel="external">"Geriatric bipolar disorder: General principles of treatment", section on 'Information for patients'</a>.)</p><p class="headingAnchor" id="H1033965"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The minimum age used to define geriatric bipolar disorder is generally 50 to 60 years. The clinical features of geriatric bipolar disorder differ from those of younger patients in that cognitive impairment and comorbid general medical illnesses are more common in geriatric patients, whereas comorbid anxiety and substance use disorders may be less common in geriatric patients. (See <a class="local">'Geriatric bipolar disorder'</a> above and  <a class="medical medical_review" href="/d/html/14650.html" rel="external">"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder is a highly recurrent illness. For geriatric bipolar patients, we recommend maintenance treatment rather than no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Maintenance treatment usually consists of the same medication regimen that induced remission. (See <a class="local">'Choosing treatment'</a> above and <a class="local">'Choosing pharmacotherapy following recovery from mood episodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For geriatric bipolar patients who remitted with a medication other than <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, and cannot tolerate maintenance treatment with the medication that induced remission, we suggest switching to lithium rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, lamotrigine is a reasonable alternative. For patients intolerant of lithium or lamotrigine, reasonable options include <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, or <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a> (See <a class="local">'Choosing pharmacotherapy following recovery from mood episodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving maintenance pharmacotherapy, we suggest adding psychotherapy rather than using pharmacotherapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjunctive psychotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians should regularly monitor remitted geriatric bipolar patients for recurrence of manic and depressive symptoms as well as medication side effects and cognitive decline. Particular attention is given to suicidal ideation and psychotic symptoms. For stable patients, we progressively lengthen the interval between assessments. (See <a class="local">'Monitoring the patient'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most geriatric bipolar patients require maintenance treatment for years, and some patients require it for their entire lives. The duration is generally longer in patients with residual symptoms (particularly suicidal ideation), ongoing comorbid psychopathology, psychosocial stressors, a history of suicide attempts, a greater number of prior mood episodes, a history of longer or more severe (eg, psychotic) mood episodes, and onset of bipolar disorder at an early age. (See <a class="local">'Duration and discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent symptoms or mood episodes during maintenance pharmacotherapy for geriatric bipolar disorder are initially treated by optimizing medication doses. If this does not control symptoms within two to eight weeks, the recurrence is treated as a new acute mood episode. (See <a class="local">'Treating recurrences'</a> above and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'</a> and  <a class="medical medical_review" href="/d/html/16446.html" rel="external">"Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Bipolar major depression'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin North Am 2011; 34:319.</a></li><li><a class="nounderline abstract_t">Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv 2004; 55:1014.</a></li><li class="breakAll">United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section. http://esa.un.org/unpd/wpp/index.htm (Accessed on June 14, 2011).</li><li><a class="nounderline abstract_t">Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999; 56:848.</a></li><li><a class="nounderline abstract_t">Young RC, Schulberg HC, Gildengers AG, et al. Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. Bipolar Disord 2010; 12:56.</a></li><li><a class="nounderline abstract_t">Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord 2004; 6:343.</a></li><li><a class="nounderline abstract_t">Prabhakar D, Balon R. Late-onset bipolar disorder: a case for careful appraisal. Psychiatry (Edgmont) 2010; 7:34.</a></li><li><a class="nounderline abstract_t">Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord 2015; 17:689.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Broadhead J, Jacoby R. Mania in old age: A first prospective study. Int J Geriatr Psychiatry 1990; 5:215.</a></li><li><a class="nounderline abstract_t">Burt T, Prudic J, Peyser S, et al. Learning and memory in bipolar and unipolar major depression: effects of aging. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:246.</a></li><li><a class="nounderline abstract_t">Young RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord 2007; 9:301.</a></li><li><a class="nounderline abstract_t">Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006; 163:319.</a></li><li><a class="nounderline abstract_t">Al Jurdi RK, Marangell LB, Petersen NJ, et al. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry 2008; 16:922.</a></li><li><a class="nounderline abstract_t">Oostervink F, Boomsma MM, Nolen WA, EMBLEM Advisory Board. Bipolar disorder in the elderly; different effects of age and of age of onset. J Affect Disord 2009; 116:176.</a></li><li><a class="nounderline abstract_t">Angst J, Gamma A, Sellaro R, et al. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003; 253:236.</a></li><li><a class="nounderline abstract_t">Takeshima M, Kurata K. Late-life bipolar depression due to the soft form of bipolar disorder compared to unipolar depression: an inpatient chart review study. J Affect Disord 2010; 123:64.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE Clinical Guideline 185, 2014. http://guidance.nice.org.uk/cg185 (Accessed on December 31, 2014).</li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Shulman KI, Almeida OP, Herrmann N, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report. Bipolar Disord 2019; 21:117.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65:432.</a></li><li><a class="nounderline abstract_t">Sajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry 2005; 13:305.</a></li><li><a class="nounderline abstract_t">BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.</a></li><li><a class="nounderline abstract_t">Ketter TA, Sarma K, Silva R, et al. LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety 2016; 33:424.</a></li><li><a class="nounderline abstract_t">Forester BP, Sajatovic M, Tsai J, et al. Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. Am J Geriatr Psychiatry 2018; 26:150.</a></li><li><a class="nounderline abstract_t">Morlet E, Costemale-Lacoste JF, Poulet E, et al. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study. J Affect Disord 2019; 259:210.</a></li><li class="breakAll">Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38, July, 2006. http://guidance.nice.org.uk/CG38 (Accessed on October 01, 2011).</li><li><a class="nounderline abstract_t">Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008; 118:347.</a></li><li><a class="nounderline abstract_t">American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.</a></li><li><a class="nounderline abstract_t">Samamé C, Martino DJ, Strejilevich SA. A quantitative review of neurocognition in euthymic late-life bipolar disorder. Bipolar Disord 2013; 15:633.</a></li><li><a class="nounderline abstract_t">Velosa J, Delgado A, Finger E, et al. Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses. Acta Psychiatr Scand 2020; 141:510.</a></li><li><a class="nounderline abstract_t">Gerhard T, Devanand DP, Huang C, et al. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry 2015; 207:46.</a></li><li><a class="nounderline abstract_t">Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65:1331.</a></li><li><a class="nounderline abstract_t">Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198:351.</a></li><li class="breakAll">Sajatovic M, Kessing LV. Bipolar disorder in the elderly. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.488.</li><li><a class="nounderline abstract_t">Sajatovic M, Blow FC, Kales HC, et al. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. Int J Geriatr Psychiatry 2007; 22:992.</a></li><li><a class="nounderline abstract_t">Young RC, Gyulai L, Mulsant BH, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry 2004; 12:342.</a></li><li class="breakAll">American Psychiatric Association Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition, 2002. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf (Accessed on January 16, 2017).</li></ol></div><div id="topicVersionRevision">Topic 16645 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536161" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Geriatric bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15345761" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15345761" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884891" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148867" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15383127" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bipolar disorder in older adults: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386635" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Late-onset bipolar disorder: a case for careful appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384588" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384588" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mania in old age: A first prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11186160" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Learning and memory in bipolar and unipolar major depression: effects of aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430306" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age and ratings of manic psychopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449489" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978253" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a "recovered" status in the systematic treatment enhancement program for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19087895" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bipolar disorder in the elderly; different effects of age and of age of onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504992" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrence of bipolar disorders and major depression. A life-long perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716179" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Late-life bipolar depression due to the soft form of bipolar disorder compared to unipolar depression: an inpatient chart review study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19716179" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Late-life bipolar depression due to the soft form of bipolar disorder compared to unipolar depression: an inpatient chart review study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30375703" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: An ISBD task force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096085" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15845756" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maintenance treatment outcomes in older patients with bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092882" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26918425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146409" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31446382" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31446382" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: A cross-sectional multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727689" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11958165" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Practice guideline for the treatment of patients with bipolar disorder (revision).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23651122" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A quantitative review of neurocognition in euthymic late-life bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954065" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614530" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981345" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lithium treatment and risk of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21525519" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21525519" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17323327" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249272" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacotherapy of bipolar disorder in old age: review and recommendations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
